T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias
CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include cancer cells becoming resistant to the therapy. Resistance mechanisms to the existing CD20 therapies include loss of target antigen expression from the cell surface, loss of antibody epitope, or modulation of antibody epitope – all of which make the malignant cells “invisibleâ€...
Source: NIH OTT Licensing Opportunities - August 19, 2020 Category: Research Authors: ott-admin Source Type: research
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional chemotherapy and radiotherapy. One of the major immune cell types present in the PDA microenvironment is a subset of macrophages commonly termed tumor-associated macrophages (TAM). TAMs originate, in part, from circ ulating monocytes upon activation by CCL2, a chemotactic chemokine...
Source: NIH OTT Licensing Opportunities - August 17, 2020 Category: Research Authors: ott-admin Source Type: research
Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies
Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA. Gene therapy using the CRX-AAV vector to retinal organoids derived from induced pluripotent stem cells (iPSCs) of a patient with the dominant CRX-I138fs mutation partially restored expression of visual opsins and...
Source: NIH OTT Licensing Opportunities - August 17, 2020 Category: Research Authors: ott-admin Source Type: research
Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice
Mesothelin (MSLN) is an antigen highly expressed in several human cancers including mesotheliomas, ovarian cancers and pancreatic cancers. As such, human MSLN (hMSLN) is a target for many anti-cancer drugs. Most therapeutics targeting hMSLN do not recognize the mouse isoform of MSLN (mMSLN) and therefore cannot be tested in mouse cancer models. Â Investigators at the National Cancer Institute (NCI) have developed a mouse model wherein mice are genetically engineered to express hMSLN in the thyroid gland under the transcriptional control of a thyroid-specific (Tpo) gene promoter. Due to the tolerance to the hMSLN isoform, t...
Source: NIH OTT Licensing Opportunities - August 17, 2020 Category: Research Authors: ott-admin Source Type: research
Use and Preparation of CD206 Small Molecule Modulators as Therapeutics for CD206-Expressing Cancers
Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional chemotherapy and radiotherapy. The major immune cell type present in the PDA microenvironment is a subset of macrophages commonly termed tumor-associated macrophages (TAM). TAMs originate from circulating monocytes upon activation by CCL2, a chemotactic chemokine secreted and then ...
Source: NIH OTT Licensing Opportunities - August 17, 2020 Category: Research Authors: ott-admin Source Type: research
Therapeutic Immunotoxins with Increased Half-Life and Anti-Tumor Activity
Recombinant Immunotoxins (RITs) are chimeric molecules composed of an antigen binding domain and toxin. The antigen binding domain component targets the cancer cell and delivers the toxin component to the cell. However, the efficacy of RITs is limited by their short half-life once they are in the patient. To address this problem, investigators at the National Cancer Institute (NCI) increased the half-life of RITs using polyethylene glycol (PEG).In specific embodiments, the antigen-binding fragment targets mesothelin, and the toxin is a fragment of Pseudomonas exotoxin (PE). Mesothelin is highly expressed in many human canc...
Source: NIH OTT Licensing Opportunities - August 17, 2020 Category: Research Authors: ott-admin Source Type: research
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy. Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 single domain antibodies (also known as nanobodies) from novel camel and rabbit single domain (VHH) libraries by phage display.  Nanobodies are the smallest known antigen-binding fragments of antibodies. Due to their sma...
Source: NIH OTT Licensing Opportunities - August 17, 2020 Category: Research Authors: ott-admin Source Type: research
A Method To Label Heparan Sulfate Proteoglycan In The Plasma Membrane Of Mammalian Cells
ID: E-143-2019-0Linked ID: TAB-3417A Method To Label Heparan Sulfate Proteoglycan In The Plasma Membrane Of Mammalian CellsBetty B Tong, Ph.D.tongb@niddk.nih.govPhone: 301-451-7836Inventors: Qi Zhang (NIDDK), Yihong Ye (NIDDK)Lead Inventors: Qi Zhang (NIDDK)Co-Inventors: Yihong Ye (NIDDK)This technology allows a rapid way to detect HSPG on cell surface in live cellsThis is a faster and more cost effective technology which can also be used in live cell imaging to track HSPG-dependent endocytosis of cargo proteins compared to the current practices which use HSPG antibodies to label HSPGThis technolog...
Source: NIH OTT Licensing Opportunities - August 13, 2020 Category: Research Authors: ott-admin Source Type: research
A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells
Heparan sulfate proteoglycan (HSPG) is a group of lipid-anchored proteoglycans, engaged in a variety of key biological functions on cell surface. HSPG-mediated endocytosis of neurotoxic protein aggregates has been linked to aging related neurodegenerative diseases. Labeling HSPG is a promising technique to trace cell profile in cell research, monitor its trafficking in live cells and in tissues. Researchers at the NIDDK have discovered a method in which a positively charged fluorescent protein binds specifically to HSPG on cell surface. This is a promising cost-effective technique that will help scientists to monitor the f...
Source: NIH OTT Licensing Opportunities - August 13, 2020 Category: Research Authors: ott-admin Source Type: research
A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells
Heparan sulfate proteoglycan (HSPG) is a group of lipid-anchored proteoglycans, engaged in a variety of key biological functions on cell surface. HSPG-mediated endocytosis of neurotoxic protein aggregates has been linked to aging related neurodegenerative diseases. Labeling HSPG is a promising technique to trace cell profile in cell research, monitor its trafficking in live cells and in tissues. Researchers at the NIDDK have discovered a method in which a positively charged fluorescent protein binds specifically to HSPG on cell surface. This is a promising cost-effective technique that will help scientists to monitor the f...
Source: NIH OTT Licensing Opportunities - August 13, 2020 Category: Research Authors: ott-admin Source Type: research
Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine
NIH inventors at the Vaccine Research Center have developed a novel influenza virus hemagglutinin (HA)-ferritin nanoparticle influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies against multiple strains of influenza. This novel influenza nanoparticle vaccine elicited two types of broadly neutralizing, cross-protective antibodies, one directed to the highly conserved HA stem and a second proximal to the conserved receptor binding site (RBS) of the viral HA, providing a new platform for universal and seasonal influenza. In addition, HA-ferritin nanoparticles can be easi...
Source: NIH OTT Licensing Opportunities - August 3, 2020 Category: Research Authors: ott-admin Source Type: research
Antisense Oligonucleotides against Cancer Cell Migration and Invasion
Advanced stage cancers are typically marked by metastases of the primary cancer to secondary sites such as lungs, liver, and bones. Such metastatic cancers result in strikingly low 5-year survival rates, underscoring the need for novel therapeutics. For example, bone metastasis of primary breast cancer has a 5-year survival rate of 13%, lung cancer only 1%. There is a need for targeted therapy options specific to metastases. One approach to targeting metastases is to reduce cancer cell migration and invasion.Several mRNAs become localized to subcellular destinations during the metastatic process. These mRNAs may play roles...
Source: NIH OTT Licensing Opportunities - July 21, 2020 Category: Research Authors: ott-admin Source Type: research
Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein
This CDC developed Limiting-Antigen avidity Enzyme Immunoassay (LAg-avidity-EIA) provides an easy way to measure increasing binding strength (avidity) of HIV antibodies as part of maturation HIV antibodies after seroconversion, providing a method to distinguish early-stage from long-term HIV-1 infection. Surveillance of HIV-1 provides information on prevalence rates of the disease, but determination of new infection rates (HIV-1 incidence) is difficult to deduce. Longitudinal follow up is expensive and can be biased.Unlike assays which use antigens derived from only one subtype and use two wells, this new approach employs ...
Source: NIH OTT Licensing Opportunities - July 9, 2020 Category: Research Authors: ott-admin Source Type: research
Monoclonal Antibodies that Neutralize B. anthracis Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)
Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as " protective antigen " (PA) and 2 catalytic proteins known as " lethal factor " (LF) and " edema factor " (EF). Although production of an efficient anthrax vaccine is an ultimate goal, the benefits of vaccination can be expected only if a large proportion of the population at risk is immunized. The low incidence of anthrax suggests that large-scale vaccination may not be...
Source: NIH OTT Licensing Opportunities - July 9, 2020 Category: Research Authors: ott-admin Source Type: research
Altering the Immune Hierarchy for Human Immunodeficiency Virus (HIV) Vaccine Development by Targeting V1V2 Regions
The development of an effective human immunodeficiency virus (HIV) vaccine has been an ongoing area of research. Sequence diversity and immunodominance are major obstacles in the design of an effective vaccine against HIV. Researchers at the National Cancer Institute (NCI) have developed a vaccine that overcomes these major obstacles by utilizing the combination of DNA and protein targets directed to the conserved HIV regions. Â Â Previous studies by NCI have demonstrated that co-administration of DNA expressing Gag and Env proteins elicits a protective immune response and reduces infection burden. Env, which mediates vir...
Source: NIH OTT Licensing Opportunities - July 7, 2020 Category: Research Authors: ott-admin Source Type: research
